These integrated approaches hold the potential to eradicate residual cancer cells and extend disease (progression)-free survival, particularly for patients with early-stage or locally advanced RET-altered solid tumors, drawing valuable insights from the management of EGFR/ALK-altered NSCLC.33–35 Moreover, SY-5007’s potential in neoadjuvant therapy also merits exploration. The gene discussed is RET; the disease is non-small cell lung carcinoma.